News

Gujarat Terce Laboratories Limited clarified that the re-appointment of Mr. Aalap Prajapati as Managing Director & Chief Executive Officer will be for a period of three years, commencing from October 28, 2026, to October 27, 2029, correcting a previous announcement made on May 29, 2026, which incorrectly stated a five-year tenure. Shareholders approved the re-appointment at the company`s 41st Annual General Meeting held on August 21, 2026.

Gujarat Terce Laboratories Limited announced that its members approved the re-appointment of Mr. Aalap Prajapati as Managing Director & CEO for three years, effective October 28, 2026, to October 27, 2029, at the company`s 41st Annual General Meeting held on August 21, 2026. Mr. Prajapati, who holds director identification number 08088327, has over 15 years of experience in the pharmaceutical sector and is the son of Whole-Time Director Mr. Natwarbhai Prajapati.

Net Loss of Gujarat Terce Laboratories reported to Rs 0.18 crore in the quarter ended June 2026 as against net loss of Rs 0.04 crore during the previous quarter ended June 2025. Sales declined 17.05% to Rs 9.00 crore in the quarter ended June 2026 as against Rs 10.85 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales9.0010.85 -17 OPM %-5.44-0.09 - PBDT-0.040.03 PL PBT-0.15-0.07 -114 NP-0.18-0.04 -350 Powered by Capital Market - Live News

Gujarat Terce Laboratories will hold a meeting of the Board of Directors of the Company on 7 August 2026.

Gujarat Terce Laboratories announced that the Annual General Meeting(AGM) of the company will be held on 21 August 2026.